Rabies treatment of health care staff

Mirjana Stantic-Pavlinic
Institute of Public Health of Ljubljana, Department of Epidemiology, Ljubljana, Slovenia

Summary

This article deals with post-exposure treatment of contacts of human cases of rabies. Experience suggests that rabies is hardly ever transmitted from person to person if at all. With the modern generation of vaccines against rabies, the use of post-exposure treatment is more widespread. A lot of contacts of patients with rabies in developed countries are treated, most of them being health care workers. This treatment is however not practised so often in developing countries where the supply of highly protective vaccines with a few side effects is low. According to reports good hygienic practice in nursing these patients is well established.

Key words: health care staff; post-exposure treatment; rabies; rabies vaccines

Introduction

All over the world we are becoming increasingly aware that we are at risk from many new and some re-emerging old infectious agents. At the end of the 20th century many different infectious diseases have been recognised as a threat to public health [1] and health care staff. Some of them are preventable by hygienic measures, chemoprophylaxis or vaccinations. For some other infectious diseases however, development of new vaccines is still in progress.

In this world of mass migration and global travel, any emerging or re-emerging infectious disease can be a threat to health care workers. Medical professionals are extremely concerned about occurrence, causes, and consequences of emerging and re-emerging infectious diseases. Tuberculosis, hepatitis C, AIDS, some haemorrhagic fevers, infectious diarrhoeas including cholera, and malaria, affect millions of people worldwide. Most of these diseases can also be transmitted to health care workers.

Vaccines against hepatitis B and against influenza are routinely used worldwide for prevention of infectious diseases among health care workers. Some vaccines are used only rarely or in epidemiological indications – vaccine against meningococcal diseases, diphtheria, whooping cough, rubella and also rabies.

Epidemiology

Rabies is classified into re-emerging infectious diseases. It is present almost all over the world [2]. The disease has re-emerged as a threat due to several recent epidemics affecting wild animals. The situation with rabies is still serious in the Russian Federation and is re-emerging in animals particularly in some parts of the USA, Central America and Asia.

Each year about 35,000 to 100,000 human rabies deaths occur around the world, and more than 6.5 million people need post-exposure treatment (PET). Most of the rabies cases could be prevented by efficient treatment [3].
Protection of health-care personnel

How to protect health care personnel from the possibility of contracting some infectious diseases, including rabies, is a matter of continuous discussion. These discussions focus on health care personnel, their managers and expert workers, responsible for prevention of hospital infections.

Some vaccines, which are used for exposed health care personnel, we can learn about from elementary medical books; for other vaccines, such as rabies vaccine, we can rarely find reports in medical journals.

Pre- and post-exposure treatment

In Europe, where human cases are rarely seen, and are usually imported [7, 8], pre-exposure treatment of health care personnel is not indicated. In a case of care for the patient with laboratory or histologically-confirmed rabies, the post-exposure treatment of all contacts including the health care personnel is practised [4–6]. The same practice is also used in the United States [9], Chile [10] and other parts of the world. The average number of contacts (hospital staff, family and other contacts) that require post-exposure treatment is approximately 50 per case in France [5] and between 41 and 55 per case in the United States [11]. The highest number of 209 post-exposure treatment in Europe was observed in France; in the United States this number was even higher and reached 290 treated after contact with one case of human rabies.

Delays in diagnosis greatly increase the number of contacts that require post-exposure treatment. The number of people in contact with humans with rabies can be high because of intensive medical care, longer survival times and care in two or more hospitals. Many request rabies prophylaxis [12, 13] and most of them are health care personnel.

In underdeveloped countries, the situation is somewhat different. The procedure is based on health education with emphasis on preventative measures. These measures are designed to prevent transmission amongst family members, particularly when a patient with rabies is cared for at home [14]. Data of post-exposure treatment of contacts are missing.

As we can see from experiences and practices in developed and underdeveloped countries, there are some discrepancies in statements on this subject. Rabies virus is present in variety of human fluids and tissues, but there are only eight well-documented reports of human to human transmission in corneal transplant recipients [6, 15]. Two non-laboratory confirmed cases of human-to-human transmission were described in the year 1996 in Ethiopia [16]. The route of exposure was direct salivary contact from another human – a kiss and a bite.

It is vitally important that all preventive measures are applied particularly when working with infected saliva, other tissue and fluids of rabid patients (use of gloves, protective glasses/goggles, mask, careful and thorough procedure with devices during aspiration). Specific post-exposure rabies treatment with vaccines and human rabies immunoglobulins are sometimes considered as well [13].

In the public health sector, we have had very good experience in post-exposure treatment against rabies with highly purified tissue culture rabies vaccines [3]. These experiences are welcomed worldwide and the positive impact of the 2nd generation cell culture rabies vaccines in controlling human rabies is obvious.

Some infectious diseases are very rarely transmitted from human to human; or this route of transmission is difficult to prove [17]. Safe and efficient cell-culture rabies vaccines are available [18, 19] – therefore, if post-exposure treatment is indicated for health care personnel, this should be carried out using one of these modern vaccines and by no means with substandard nerve tissue derived rabies vaccines.

Correspondence:
Mirjana Stantic-Pavlinic MD MSc
Institute of Public Health of Ljubljana
Department of Epidemiology
Zaboka 29
SLO-1000 Ljubljana
E-Mail: stantic@bigfoot.com
References

The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

Impact factor Swiss Medical Weekly

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch